Salarius Pharmaceuticals, Inc.
SLRX
$0.83
-$0.02-2.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -873.50K | -957.80K | -1.71M | -1.46M | -972.10K |
| Total Depreciation and Amortization | 1.10K | 1.10K | 1.10K | 1.10K | 1.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.80K | 23.20K | 33.50K | 51.00K | 60.00K |
| Change in Net Operating Assets | -797.20K | 71.30K | 493.20K | 669.30K | -445.70K |
| Cash from Operations | -1.65M | -862.30K | -1.18M | -742.50K | -1.36M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -200.00K | -- | -- | -- | -- |
| Cash from Investing | -200.00K | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -112.20K | -109.60K | -107.00K | -69.90K |
| Issuance of Common Stock | 5.86M | -- | 655.20K | 0.00 | 1.44M |
| Repurchase of Common Stock | -- | -29.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.86M | -141.20K | 545.60K | -107.00K | 1.37M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.01M | -1.00M | -636.10K | -849.50K | 11.20K |